QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DNTH

QT43Dianthus Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
82.49
+0.60+0.73%
OverviewShort InterestFilings
DNTHQT43Dianthus Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
82.49+0.73%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.88
Insider Own14.45%
Shs Outstand54.67M
Perf Week7.90%
Market Cap3.42BForward P/E-EPS next Y-4.48Insider Trans0.93%Shs Float-Perf Month-3.71%
Enterprise Value2.79BPEG-EPS next Q-0.85Inst Own-Short Float-Perf Quarter3.11%
Income-9914832.00P/S2559.06EPS this Y-30.17%Inst Trans-Short Ratio-Perf Half Y99.25%
Sales1.34MP/B3.27EPS next Y-19.44%ROA-0.91%Short Interest-Perf YTD100.17%
Book/sh21.97P/C-EPS next 5Y-ROE-1.78%52W High96.50 -14.52%Perf Year377.65%
Cash/sh20.32P/FCF-EPS past 3/5Y-ROIC-15.82%52W Low16.64 395.73%Perf 3Y-
Dividend Est.-EV/EBITDA-257.10Sales past 3/5Y-30.66% -Gross Margin94.31%Volatility3.75% 5.40%Perf 5Y-
Dividend TTM-EV/Sales2090.27EPS Y/Y TTM-61.96%Oper. Margin-14318.04%ATR (14)5.49Perf 10Y-
Dividend Ex-Date-Quick Ratio29.25Sales Y/Y TTM0.00%Profit Margin-847.53%RSI (14)48.34Recom1.83
Dividend Gr. 3/5Y-Current Ratio29.25EPS Q/Q-3.66%SMA20-1.83%Beta1.23Target Price115.00
Payout0.00%Debt/Eq0.00Sales Q/Q-100.00%SMA50-4.96%Rel Volume3.30Prev Close81.89
Employees78LT Debt/Eq0.00EarningsAug 06SMA20043.56%Avg Volume750.08KPrice82.49
IPO DateJun 21, 2018Option/ShortYes / YesEPS/Sales Surpr.27.35% -Net Debt/EBITDA57.66Volume2,478,036Change0.73%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedJefferiesBuy$110 → $132
May-11-26ReiteratedEvercore ISI$122 → $120
May-06-26ReiteratedRaymond JamesStrong Buy$123 → $125
Apr-08-26InitiatedWolfe ResearchOutperform$98
Mar-10-26UpgradeRaymond JamesOutperform → Strong Buy
Mar-09-26ReiteratedUBS$81 → $98
Mar-09-26ReiteratedJefferiesBuy$51 → $98
Mar-09-26ReiteratedRobert W. Baird$67 → $132
Mar-09-26ReiteratedH.C. Wainwright$47 → $130
Mar-09-26ReiteratedStifel Nicolaus$120
Latest News
Jun-12-26
Jun-12-2601:20PM
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Benzinga
Jun-11-26
Jun-11-2610:13AM
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable QuestionsSeekingAlpha
10:13AM
Dianthus Therapeutics: Sanofi's CIPD Study Fail Poses Uncomfortable QuestionsSeekingAlpha
09:09AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga
09:09AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga
Jun-10-26
Jun-10-2608:05AM
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue626
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit626
Selling, General and Administrative Excl. Other273425
Research and Development9714683
Other Operating Expense
-100
Operating Income-117-178-102
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-17-16-17
Net Income Before Taxes-101-162-85
Income Taxes
000
Consolidated Net Income-101-162-85
Net Income From Continuing Operations-101-162-85
Net Income-101-162-85
EPS (Recurring)-2.88-4.20-2.55
EPS (Basic, Before Extraordinaries)-2.88-4.20-2.55
EPS (Diluted)-2.88-4.20-2.55
EBITDA-99-162-85
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio494.94782.99—
Gross Margin100.00100.00100.00
Operating Margin-1,950.00-8,900.00-1,700.00
Net Margin-1,683.33-8,100.00-1,416.67
Shares Outstanding363833
Market Capitalization2,9701,566—
Operating Lease Expense
———
Insider Trading Volume
$86.05$81.73$77.41$73.10$68.78● Close Price0.00M7.01M14.01M21.02M28.03MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Randhawa SimratEVP, Head of R&DJun 01 '26Option Exercise18.8553,0601,000,41096,875Jun 02 12:00 AM
Randhawa SimratEVP, Head of R&DJun 01 '26Sale90.6226,5302,404,0774,000Jun 02 12:00 AM
Soteropoulos PaulaDirectorMay 08 '26Option Exercise8.441,19810,112599May 11 12:00 AM
Soteropoulos PaulaDirectorMay 08 '26Sale85.4759951,1970May 11 12:00 AM
Savitz RyanEVP, CFO & CBOApr 09 '26Option Exercise17.8816,448294,09071,776Apr 10 12:00 AM
Savitz RyanEVP, CFO & CBOApr 09 '26Sale89.848,224738,8440Apr 10 12:00 AM
Savitz RyanEVP, CFO & CBOMar 31 '26Option Exercise11.74228,7342,685,714114,367Apr 01 12:00 AM
Savitz RyanEVP, CFO & CBOMar 31 '26Sale83.00114,3679,492,5950Apr 01 12:00 AM
Soteropoulos PaulaDirectorMar 31 '26Option Exercise8.441,19810,112599Apr 01 12:00 AM
Soteropoulos PaulaDirectorMar 31 '26Sale80.1159947,9860Apr 01 12:00 AM
Soteropoulos PaulaDirectorMar 24 '26Option Exercise8.4455,188465,78627,594Mar 26 12:00 AM
Soteropoulos PaulaDirectorMar 24 '26Sale78.0527,5942,153,7120Mar 26 12:00 AM
Garcia MarinoCEO AND PRESIDENTMar 16 '26Option Exercise7.66130,584999,950269,408Mar 17 12:00 AM
CARR EDWARDCHIEF ACCOUNTING OFFICERMar 12 '26Option Exercise20.4587,3641,786,51863,818Mar 13 12:00 AM
Garcia MarinoCEO AND PRESIDENTMar 12 '26Option Exercise6.70245,8361,647,102122,918Mar 13 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR